Glaukos 10-Q Confirms Q3 Sales of $211.0M (+58%) and First Quarterly Profit of $2.0M
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (2.2× avg).
Summary
Glaukos' Q3 10-Q confirms $211.0 million of sales (+58%) and a $2.0 million net profit, with operating cash flow turning positive at $40.9 million for nine months. The filing also discloses new 10b5-1 selling plans for the CEO, President/COO and CFO starting in November 2026.
Key Events · Earnings and Guidance · GKOS
-
Q3 Sales Jump 58% to $211.0M
Net sales rose to $211.0 million from $133.5 million, driven by U.S. glaucoma sales of $118.6 million (+47%) and corneal health sales of $59.0 million (+154%) as Epioxa replaced Photrexa.
-
First Quarterly Profit: $2.0M
Net income of $2.0 million, or $0.03 per diluted share, versus a $16.2 million loss a year earlier; gross margin expanded to 85% from 78%.
-
Operating Cash Flow Turns Positive
Nine-month operating cash flow was $40.9 million provided versus $21.6 million used in the prior-year period; cash, equivalents, short-term investments and restricted cash totaled $339.8 million at September 30, 2026.
-
New Insider Selling Plans Disclosed
CEO Thomas Burns adopted a 10b5-1 plan for up to 280,000 shares, President/COO Joe Gilliam 59,890 shares and CFO Alex Thurman 17,752 shares, with sales commencing November 12-18, 2026.
Analysis · GKOS · Industrial Applications And Services
The 10-Q puts hard numbers behind the preliminary release: Q3 net sales of $211.0 million, up 58% from $133.5 million, with gross margin at 85% versus 78% a year ago. More important, Glaukos swung to a $2.0 million net profit ($0.03 per diluted share) from a $16.2 million loss, and nine-month operating cash flow flipped to $40.9 million provided from $21.6 million used. That is the first real evidence the iDose TR and Epioxa launches can carry the P&L, not just the top line. Against that, the filing discloses new 10b5-1 plans for the CEO (280,000 shares), President/COO (59,890) and CFO (17,752) beginning in November 2026 — scheduled sales that follow a 90-day stretch of roughly $17.3 million in net insider selling and could weigh on sentiment even as fundamentals improve.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GKOS was trading at $215.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $73.16 to $191.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.